What is Transgene?
Transgene operates as a specialized biotechnology entity focused on the design and development of innovative immunotherapies. The company utilizes a sophisticated technological stack, including its proprietary myvac platform and the Invir.IO oncolytic virus framework, to address complex oncological challenges. By integrating genetic engineering with artificial intelligence, Transgene aims to deliver highly personalized therapeutic solutions that enhance treatment efficacy for patients with diverse cancer profiles. The firm's market position is defined by its ability to bridge the gap between advanced molecular research and clinical application, effectively targeting the growing demand for precision medicine in the global healthcare sector.
How much funding has Transgene raised?
Transgene has raised a total of $144M across 2 funding rounds:
Debt
$22.4M
Stock/Share Issuance
$121.6M
Debt (2016): $22.4M with participation from European Investment Bank
Stock/Share Issuance (2025): $121.6M led by Dassault Group
Key Investors in Transgene
European Investment Bank
Established in 1958 and headquartered in Luxembourg, European Investment Bank (EIB) is the European Union's nonprofit long-term lending and finance institution.
Dassault Group
Dassault Group is a French industrial conglomerate with deep roots in aerospace and technology, providing strategic capital to high-growth enterprises.
What's next for Transgene?
Looking ahead, the strategic deployment of this recent financing will likely focus on the expansion of clinical trials and the optimization of manufacturing processes for personalized vaccines. As the company transitions into a more mature phase of enterprise-level operations, the focus will shift toward regulatory milestones and potential commercialization pathways for its lead candidates. Investors and stakeholders will be monitoring the progression of the TG4050 program, as it represents a critical component of the company's growth strategy. The integration of AI-driven insights into their development cycle is expected to further streamline the path to market, potentially establishing new benchmarks for efficacy in the immunotherapy space.
See full Transgene company page
